The company was fined 300 thousand rubles
The Federal Antimonopoly Service (FAS) saw in the advertising of the drug “Ginkoum” from the company “Evalar” violations of the law on advertising. This was reported by the press service of the department. FAS fined the company for 300 thousand rubles.
Advertising of the drug was shown on the TV channels “Russia 1” and “NTV”. In the video, “Evalar” “guaranteed the positive effect of the drug and its effectiveness in the treatment of diseases of the veins and blood.”
The FAS noted that, by law, advertising should not guarantee the positive effect of the product, as well as its safety, effectiveness and the absence of side effects.
The company said they do not agree with this decision and will appeal it.
Read also
FAS filed a case against TNT due to high-profile advertising
Previously, the FAS has already held Evalar liable for improper advertising of Ginkoum in 2019. Then the company was fined 200 thousand rubles. The regulator decided that Evalar distributed inappropriate contextual advertising of Ginkoum in the Yandex.Direct service. The advertisement indicated that the drug was cheaper than its counterparts and eliminated headaches, dizziness and tinnitus.
The active substance of “Ginkoum” is a dry extract of the leaves of Ginkgo biloba, which is widely used in traditional Chinese medicine. The company recommends using the drug to improve memory, improve concentration and intellectual abilities.
